These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24560457)

  • 1. Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy.
    Baldo G; Giugliani R; Matte U
    Med Hypotheses; 2014 Apr; 82(4):478-80. PubMed ID: 24560457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
    Dickson PI
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal storage disorders: 4 big questions.
    Eisenstein M
    Nature; 2016 Sep; 537(7621):S165. PubMed ID: 27652787
    [No Abstract]   [Full Text] [Related]  

  • 4. [The blood-brain barrier and neurodegenerative lysosomal storage diseases].
    Urayama A
    Brain Nerve; 2013 Feb; 65(2):153-63. PubMed ID: 23399673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.
    Stroobants S; Gerlach D; Matthes F; Hartmann D; Fogh J; Gieselmann V; D'Hooge R; Matzner U
    Hum Mol Genet; 2011 Jul; 20(14):2760-9. PubMed ID: 21515587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
    Sly WS; Vogler C
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):5760-2. PubMed ID: 11983877
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
    Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
    J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of posttreatment posture.
    Jolly RD; Marshall NR; Marshall J; Hartman A; Hemsley KM; Winner LK
    Neuropathol Appl Neurobiol; 2013 Oct; 39(6):681-92. PubMed ID: 23252616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.
    Scarpa M; Bellettato CM; Lampe C; Begley DJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):159-71. PubMed ID: 25987170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal storage diseases and the blood-brain barrier.
    Begley DJ; Pontikis CC; Scarpa M
    Curr Pharm Des; 2008; 14(16):1566-80. PubMed ID: 18673198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal storage diseases: mechanisms of enzyme replacement therapy.
    Bou-Gharios G; Abraham D; Olsen I
    Histochem J; 1993 Sep; 25(9):593-605. PubMed ID: 8226100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.
    Blanz J; Stroobants S; Lüllmann-Rauch R; Morelle W; Lüdemann M; D'Hooge R; Reuterwall H; Michalski JC; Fogh J; Andersson C; Saftig P
    Hum Mol Genet; 2008 Nov; 17(22):3437-45. PubMed ID: 18713755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
    Desnick RJ; Schuchman EH
    Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for enzyme replacement therapy for lysosomal storage diseases.
    Grubb JH; Vogler C; Sly WS
    Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement.
    Rappaport J; Garnacho C; Muro S
    Mol Pharm; 2014 Aug; 11(8):2887-95. PubMed ID: 24949999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
    Muro S; Schuchman EH; Muzykantov VR
    Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.